Drug Landscape ›
SODIUM ALGINATE ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 1,507
Most-reported reactions
Fatigue — 173 reports (11.48%) Off Label Use — 166 reports (11.02%) Diarrhoea — 165 reports (10.95%) Pyrexia — 165 reports (10.95%) Nausea — 159 reports (10.55%) Rash — 153 reports (10.15%) Headache — 144 reports (9.56%) Vomiting — 129 reports (8.56%) Dyspnoea — 128 reports (8.49%) Pain — 125 reports (8.29%)
Source database →
SODIUM ALGINATE in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is SODIUM ALGINATE approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for SODIUM ALGINATE in United States?
Marketing authorisation holder not available in our data.